Similarly, the American College of Chest Physicians (ACCP) states that in patients undergoing TKA, post-surgical chemical thromboprophylaxis with low-molecular-weight heparin (LMWH) or factor Xa inhibitors is recommended for a minimum of 10 to 14 days to reduce the risk and incidence of symptomatic deep vein thrombosis (DVT) and pulmonary embolism (PE) [9]. The gene discussed is F10; the disease is deep vein thrombosis.